Compugen Ltd. (CGEN)

NASDAQ: CGEN · IEX Real-Time Price · USD
0.788
+0.068 (9.44%)
At close: Mar 21, 2023, 4:00 PM
0.780
-0.008 (-1.02%)
After-hours: Mar 21, 2023, 4:50 PM EDT
9.44%
Market Cap 73.47M
Revenue (ttm) 7.50M
Net Income (ttm) -33.69M
Shares Out 93.24M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 237,280
Open 0.730
Previous Close 0.720
Day's Range 0.701 - 0.790
52-Week Range 0.510 - 3.570
Beta 2.70
Analysts Buy
Price Target 5.76 (+630.96%)
Earnings Date Feb 27, 2023

About CGEN

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 11, 2000
Employees 73
Stock Exchange NASDAQ
Ticker Symbol CGEN
Full Company Profile

Financial Performance

In 2022, Compugen's revenue was $7.50 million, an increase of 25.00% compared to the previous year's $6.00 million. Losses were -$33.69 million, -1.49% less than in 2021.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for CGEN stock is "Buy." The 12-month stock price forecast is $5.76, which is an increase of 630.96% from the latest price.

Price Target
$5.76
(630.96% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Compugen to Present New Research Enabling Accurate Detection and Study of Novel Target PVRIG at AACR 2023

Correction of the single cell RNA sequencing GENCODE gene model enables accurate detection and study of the novel target PVRIG, advancing research that could potentially deliver new cancer immunothera...

6 days ago - PRNewsWire

Government vows aid for tech firms but Israel stocks slide on SVB collapse

Israeli shares slid more than 4% on the Tel Aviv Stock Exchange (TASE) on Sunday led by financial firms following the failure of SVB Financial Group late last week, while the government vowed to help ...

Other symbols: SIVB
1 week ago - Reuters

Compugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference

HOLON, ISRAEL , March 8, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...

1 week ago - PRNewsWire

Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept Study

Study builds on clinical benefit reported in heavily pretreated MSS CRC patients with liver metastases treated with dual combination of COM701 and nivolumab Initial findings expected by the end of 202...

2 weeks ago - PRNewsWire

Compugen Reports Fourth Quarter and Full Year 2022 Results

On track to dose the first patients in MSS CRC and PROC triple combination proof of concept studies in Q1 2023 and Q2 2023, respectively, with the combination of potential first-in-class anti-PVRIG, C...

3 weeks ago - PRNewsWire

Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3

Phase 3 study with rilvegostomig, AstraZeneca's (LSE/STO/Nasdaq:AZN) PD-1/TIGIT bi-specific derived from Compugen's COM902 is expected to start in 2023. AstraZeneca continues to expand rilvegostomig's...

Other symbols: AZN
1 month ago - PRNewsWire

Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023

HOLON, Israel , Feb. 13, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Comp...

1 month ago - PRNewsWire

Compugen to Present at the SVB Securities Global Biopharma Conference

HOLON, Israel , Feb. 9, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that managemen...

1 month ago - PRNewsWire

Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview

HOLON, Israel , Jan. 23, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Anat Cohe...

2 months ago - PRNewsWire

Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer

COM701 in combination with nivolumab ± BMS-986207 (anti-TIGIT) in heavily pretreated patient population, resulted in encouraging durable confirmed partial responses (overall response rate 20% (n=20) t...

3 months ago - PRNewsWire

Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients

At the time of abstract data cutoff, COM701+ nivolumab + BMS-986207 (anti-TIGIT) demonstrated encouraging 20% overall response rate and 40% disease control rate in heavily pretreated patients with pla...

3 months ago - PRNewsWire

Compugen to Participate in the JMP Securities Hematology and Oncology Summit

HOLON, Israel , Nov. 29, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Anat Cohe...

4 months ago - PRNewsWire

Compugen to Receive Milestone Payment Triggered by AstraZeneca's Phase 2 Initiation of PD-1/TIGIT Bispecific

Advancement of AZD2936, a PD-1/TIGIT bispecific antibody derived from COM902, into Phase 2, triggers $7.5 million milestone payment from AstraZeneca HOLON, Israel , Nov. 16, 2022 /PRNewswire/ -- Compu...

4 months ago - PRNewsWire

Compugen Reports Third Quarter 2022 Results

New encouraging preliminary clinical data, presented at SITC 2022, showing anti-tumor activity supported by potent immune activation in the tumor microenvironment following combination of COM701 and n...

4 months ago - PRNewsWire

Compugen to Participate in the Stifel Healthcare Conference

HOLON, ISRAEL , Nov. 8, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Anat Cohen...

4 months ago - PRNewsWire

Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients

Anti-tumor activity following blockade of PVRIG with COM701 when added to nivolumab is supported by potent tumor microenvironment (TME) immune activation in MSS-CRC patients typically not responding t...

4 months ago - PRNewsWire

Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients

COM701 in combination with nivolumab demonstrated encouraging 12% ORR in 3L+ MSS-CRC patients with liver metastases, compared to 0% ORR historically for other immunotherapies in a U.S. patient populat...

4 months ago - PRNewsWire

Compugen Announces Receipt of Nasdaq Delisting Notice

HOLON, Israel , Nov. 2, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that on Octobe...

4 months ago - PRNewsWire

Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022

HOLON, Israel , Oct. 31, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Comp...

5 months ago - PRNewsWire

Compugen to Present New Clinical Data at ESMO-IO

Clinical data from COM701/nivolumab ± BMS-986207 combination studies in patients with platinum resistant ovarian cancer Clinical data from COM701±nivolumab study in patients with metastatic NSCLC who ...

5 months ago - PRNewsWire

Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022

Clinical data from dual combination COM701/nivolumab MSS-CRC cohort expansion study Research data on differentiation of PVRIG from other immune checkpoints HOLON, Israel , Oct. 6, 2022 /PRNewswire/ --...

5 months ago - PRNewsWire

Compugen Letter to Shareholders

HOLON, Israel , Sept. 22, 2022 /PRNewswire/ -- Compugen Ltd.

6 months ago - PRNewsWire

Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer

HOLON, Israel , Sept. 12, 2022 /PRNewswire/ -- Compugen Ltd.

6 months ago - PRNewsWire

Compugen to Participate in Upcoming Fierce Biotech Summit

YaronTurpaz, Ph.D., SVP and Senior Advisor, Computational Discovery, Compugen to participate in a panel discussion on leveraging artificial intelligence and machine learning to advance discovery and a...

6 months ago - PRNewsWire

5 Top Stocks Cathie Wood Sold This Week

It was another down week for Cathie Wood's flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEARCA: ARKK). Shares of the ETF are finishing in the red today, marking the second straight ...

Other symbols: IRDMNNDMSGFYTSLA
7 months ago - InvestorPlace